Skip to main content
Premium Trial:

Request an Annual Quote

Syapse Partners With Ajou University Hospital to Expand Real-World Data Network in Asia

NEW YORK – Syapse said on Tuesday that it was partnering with Ajou University Hospital in South Korea to use real-world evidence to accelerate precision medicine and improve outcomes for cancer patients.

Syapse, a company that makes software to support precision oncology care, is building an international network, called the Learning Health Network, which allows healthcare providers to share real-world clinical, molecular, treatment, and outcomes data in order to improve understanding of the efficacy and safety of cancer treatments in patients who are clinically and molecularly similar. Syapse and its network partners are hoping to use this data to support clinical decisions and deliver precision cancer care. Data collected within the network can also be used to support R&D projects, clinical trial matching, regulatory filings, and post-approval monitoring.

Cancer centers and hospitals collaborating with Syapse will use its secure platform to share de-identified data that is standardized and normalized across the network and that complies with all applicable federal and state data privacy protection regulations.

This latest collaboration brings Ajou University Hospital into the Learning Health Network and expands the network's reach in South Korea.

"Syapse's health system network has been expanding as we add new partners who are focused on leveraging the value of real-world data to rapidly enhance precision medicine and improve patient outcomes," Syapse CEO Ken Tarkoff said in a statement. "We are committed to providing the most updated medical information and insights to Ajou's healthcare providers across its 10 cancer care centers, and look forward to continued growth in South Korea."

Syapse inked an agreement with another South Korean hospital, Seoul National University Hospital, in 2018. 

In May, Syapse raised $30 million in new equity investments to support its collaborations and its application of precision medicine in guiding real-world outcomes.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.